Prestige Consumer Healthcare (PBH) Depreciation & Amortization (CF) (2010 - 2025)
Prestige Consumer Healthcare's (PBH) quarterly Depreciation & Amortization (CF) came in at $7.6 million in Q4 2025, up 10.54% year-on-year from $6.9 million in Q4 2024, and down 0.93% quarter-over-quarter from $7.7 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $7.6 million for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 10.54% year-over-year to $7.6 million in Q4 2025; TTM through Dec 2025 was $30.2 million, a 1.92% decrease from a year earlier, with the FY2025 full-year figure at $30.2 million, down 1.64% from the prior year.
- Depreciation & Amortization (CF) declined to $7.6 million in Q4 2025 per PBH's latest filing, from $7.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $8.5 million in Q1 2022 and bottomed at $6.9 million in Q4 2024.
- The 5-year median for Depreciation & Amortization (CF) is $7.8 million (2024), against an average of $7.8 million.
- Across the five-year window, Depreciation & Amortization (CF) climbed 12.58% in 2022 and decreased 10.18% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $8.0 million in 2021, then gained by 0.99% to $8.1 million in 2022, then retreated by 5.95% to $7.6 million in 2023, then dropped by 10.18% to $6.9 million in 2024, then grew by 10.54% to $7.6 million in 2025.
- Per Business Quant, the three latest PBH Depreciation & Amortization (CF) figures stand at $7.6 million (Q4 2025), $7.7 million (Q3 2025), and $7.7 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Prestige Consumer Healthcare | 2.34 Bn | 2.28 Bn | 157.37 Mn | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.59 Mn |
| Dec 31, 2025 | 7.59 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Dec 31, 2024 | 6.87 Mn |
| Dec 31, 2024 | 6.87 Mn |
| Sep 30, 2024 | 7.93 Mn |
| Sep 30, 2024 | 7.93 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Mar 31, 2024 | 7.84 Mn |
| Mar 31, 2024 | 7.84 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Sep 30, 2023 | 7.64 Mn |
| Sep 30, 2023 | 7.64 Mn |